Trials / Recruiting
RecruitingNCT05615974
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
A Phase I/II, Open-label, Dose Escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of LM-101 Injection as a Single Agent or Combination Therapy in Patients With Advanced Malignant Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 139 (estimated)
- Sponsor
- LaNova Medicines Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LM101 | Administered intravenously |
| DRUG | Toripalimab | Administered intravenously |
| DRUG | Rituximab | Administered intravenously |
Timeline
- Start date
- 2023-01-11
- Primary completion
- 2027-01-11
- Completion
- 2028-01-11
- First posted
- 2022-11-14
- Last updated
- 2024-12-19
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05615974. Inclusion in this directory is not an endorsement.